For research use only. Not for therapeutic Use.
NYX-2925（Cat No.:I041317）is an investigational oral therapeutic agent being developed by Nyxol Pharmaceuticals for the treatment of chronic pain conditions, particularly those associated with neuropathic pain. It works by modulating the function of specific receptors in the nervous system to restore normal pain signaling. By targeting pathways involved in central sensitization, NYX-2925 aims to reduce pain perception and improve quality of life for patients suffering from conditions like diabetic neuropathy and fibromyalgia. Early-phase clinical trials have shown promise in its ability to provide significant pain relief with a favorable safety profile.
| CAS Number | 2012536-16-0 |
| Synonyms | (2S,3R)-3-hydroxy-2-[(4R)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide |
| Molecular Formula | C14H23N3O4 |
| Purity | ≥95% |
| IUPAC Name | (2S,3R)-3-hydroxy-2-[(4R)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide |
| InChI | InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m1/s1 |
| InChIKey | NFXPEHLDVKVVKA-ISTVAULSSA-N |
| SMILES | C[C@H]([C@@H](C(=O)N)N1C[C@@]2(C1=O)CCCN2C(=O)C(C)C)O |
